PD-1 and PD-1 ligands: from discovery to clinical application
- PMID: 17606980
- DOI: 10.1093/intimm/dxm057
PD-1 and PD-1 ligands: from discovery to clinical application
Abstract
Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.
Similar articles
-
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.Nat Immunol. 2007 Mar;8(3):239-45. doi: 10.1038/ni1443. Nat Immunol. 2007. PMID: 17304234 Review.
-
PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion.Eur J Immunol. 2005 Dec;35(12):3561-9. doi: 10.1002/eji.200526347. Eur J Immunol. 2005. PMID: 16278812
-
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.Nat Immunol. 2001 Mar;2(3):261-8. doi: 10.1038/85330. Nat Immunol. 2001. PMID: 11224527
-
Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases.Am J Gastroenterol. 2007 Feb;102(2):302-12. doi: 10.1111/j.1572-0241.2006.00948.x. Am J Gastroenterol. 2007. PMID: 17311651
-
Role of PD-1 in regulating T-cell immunity.Curr Top Microbiol Immunol. 2011;350:17-37. doi: 10.1007/82_2010_116. Curr Top Microbiol Immunol. 2011. PMID: 21061197 Review.
Cited by
-
Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines.Cancer Gene Ther. 2021 Sep;28(9):935-946. doi: 10.1038/s41417-021-00333-5. Epub 2021 Apr 9. Cancer Gene Ther. 2021. PMID: 33837365 Review.
-
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.Front Immunol. 2024 Feb 5;15:1340373. doi: 10.3389/fimmu.2024.1340373. eCollection 2024. Front Immunol. 2024. PMID: 38375475 Free PMC article. Review.
-
Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood-brain barrier in rodents and primates.Nat Biomed Eng. 2022 Nov;6(11):1257-1271. doi: 10.1038/s41551-022-00938-7. Epub 2022 Oct 10. Nat Biomed Eng. 2022. PMID: 36217021
-
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities.Exp Hematol Oncol. 2022 Nov 16;11(1):101. doi: 10.1186/s40164-022-00356-0. Exp Hematol Oncol. 2022. PMID: 36384676 Free PMC article. Review.
-
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).Int J Mol Med. 2016 Jul;38(1):3-15. doi: 10.3892/ijmm.2016.2620. Epub 2016 May 31. Int J Mol Med. 2016. PMID: 27245147 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
